Participant eligibility
infection, T2D
INFECTION, RECRUITMENT
Patients with T2D for >1 year, who had been on stable doses of metformin and/or sulfonylurea for >3 months were eligible to participate if they were aged 18–80 years inclusive, had HbA1c > 58 mmol/mol [> 7.5%] and < 111 mmol/mol [<12.3%], had never been on DPP4i or thiazolidinedione, had no insulin use, had no active infection requiring antibiotics, had no contraindication to either trial medication, and were able to give written informed consent. These eligibility criteria were modified to enable those on stable doses of two other types of oral glucose-lowering medications to participate in this trial (acarbose or dapagliflozin) as dual therapy with either metformin or sulfonylurea. Recruitment targeted 40% of participants being of Māori and/or Pacific ethnicity.